journal article·2024-11Open access

Gemcitabine Resistant Triple Negative Breast Tumor Derived Mesoporous Silicon Nanovaccine Overcame Drug Resistance

Wen Pan, Yangyi Wang, Shaomin Tian, Xiaopeng Ma, Yuanzeng Min

Advanced Functional Materials· Volume 34· Issue 45

Abstract

Abstract Drug resistance presents a significant challenge in cancer treatment. By far, there is no effective method to solve this issue. Therapeutic cancer vaccine, which uses tumor antigens, e.g. neoantigens, to activate the hosts’ immune system to eliminate tumor cells, may be effective for overcoming tumor resistance. So, it is hypothesized that resistant tumors may have much more abundant tumor mutations in comparison to naive tumors, and the corresponding vaccine may overcome drug resistance. The proteomics data confirmes that cell lysates from resistant tumors to gemcitabine (GEM), a model drug, contain abundant tumor‐associated antigens, tumor‐specific antigens, damage‐associated molecular patterns, and neoantigens, which can activate immune responses. Herein, to enhance antigen presentation, a mesoporous silicon nanovaccine is developed, which is loaded with antigens from GEM treated GEM‐resistant triple‐negative breast cancer 4T1 cells. When mice bearing GEM‐resistant tumors are vaccinated, the nanovaccine displays efficacy against GEM‐resistant tumors. Moreover, when combined with immunotherapy, the efficacy of the developed nanovaccine on GEM‐resistant tumors are further improved by increasing intratumoral T‐cell infiltrations. The work presents a new strategy for overcoming drug resistance using cancer nanovaccine, which broadens clinical application prospects.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Anodic Oxide Films and Nanostructures

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry University of Science and Technology of China Hefei 230026 China

Department of General Surgery The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Hefei 230026 China

Department of Microbiology & Immunology University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599‐7290 USA

The First Affiliated Hospital of USTC Division of Life Sciences and Medicine Department of Bio‐X Interdisciplinary Science at Hefei National Laboratory (HFNL) for Physical Science at the Microscale CAS Key Lab of Soft Matter Chemistry University of Science and Technology of China Hefei 230026 China

Funding

National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities · University of Science and Technology of China

References (68)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1001/jamaoncol.2017.174710.1001/jamaoncol.2017.1747 ↗
3. 10.3322/caac.2176310.3322/caac.21763 ↗
4. 10.1016/j.trecan.2018.01.00110.1016/j.trecan.2018.01.001 ↗
5. 10.1007/s00280-017-3427-110.1007/s00280-017-3427-1 ↗
6. 10.1038/s41586-019-1730-110.1038/s41586-019-1730-1 ↗
7. 10.1016/j.canlet.2014.03.01310.1016/j.canlet.2014.03.013 ↗
8. 10.3390/ijms2109323310.3390/ijms21093233 ↗
9. 10.1016/j.bbacli.2015.03.00310.1016/j.bbacli.2015.03.003 ↗
10. 10.1038/s41571-021-00565-210.1038/s41571-021-00565-2 ↗
11. 10.3390/cells809095710.3390/cells8090957 ↗
12. 10.1111/1440-1681.1258110.1111/1440-1681.12581 ↗
13. 10.1038/s41588-019-0525-510.1038/s41588-019-0525-5 ↗
14. 10.1080/14789450.2019.160156110.1080/14789450.2019.1601561 ↗
15. 10.1186/s12951-021-01146-210.1186/s12951-021-01146-2 ↗
16. 10.1038/nrclinonc.2014.11110.1038/nrclinonc.2014.111 ↗
17. 10.1038/nri.2017.13110.1038/nri.2017.131 ↗
18. 10.1038/s41541-019-0103-y10.1038/s41541-019-0103-y ↗
19. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
20. 10.2174/157489281766622041411033510.2174/1574892817666220414110335 ↗
21. 10.1038/s43018-022-00418-610.1038/s43018-022-00418-6 ↗
22. 10.1080/2162402X.2018.151150610.1080/2162402X.2018.1511506 ↗
23. 10.1158/1078-0432.CCR-18-286710.1158/1078-0432.CCR-18-2867 ↗
24. 10.1016/S0140-6736(08)60697-210.1016/S0140-6736(08)60697-2 ↗
25. 10.1016/S1470-2045(18)30254-710.1016/S1470-2045(18)30254-7 ↗
26. 10.3389/fimmu.2022.82838610.3389/fimmu.2022.828386 ↗
27. 10.1186/s12943-019-1055-610.1186/s12943-019-1055-6 ↗
28. 10.1038/s41571-020-00460-210.1038/s41571-020-00460-2 ↗
29. 10.1093/annonc/mdx68110.1093/annonc/mdx681 ↗
30. 10.1172/JCI8000810.1172/JCI80008 ↗
31. 10.1038/nature2299110.1038/nature22991 ↗
32. 10.1016/j.cell.2020.08.05310.1016/j.cell.2020.08.053 ↗
33. 10.1093/annonc/mdz253.00410.1093/annonc/mdz253.004 ↗
34. 10.1038/nature1442610.1038/nature14426 ↗
35. 10.1186/s13073-021-00872-410.1186/s13073-021-00872-4 ↗
36. 10.1038/nature1400110.1038/nature14001 ↗
37. 10.1016/j.gendis.2018.05.00310.1016/j.gendis.2018.05.003 ↗
38. 10.1038/nri221610.1038/nri2216 ↗
39. 10.1016/j.canlet.2018.08.02810.1016/j.canlet.2018.08.028 ↗
40. 10.1021/acs.chemrev.0c0038310.1021/acs.chemrev.0c00383 ↗
41. 10.1016/j.biomaterials.2023.12229010.1016/j.biomaterials.2023.122290 ↗
42. 10.1016/j.actbio.2022.10.00110.1016/j.actbio.2022.10.001 ↗
43. 10.1016/j.actbio.2023.09.01310.1016/j.actbio.2023.09.013 ↗
44. 10.1097/PPO.0b013e318233e5b210.1097/PPO.0b013e318233e5b2 ↗
45. Butterfield L. H. · BMJ · 2015 · 350
46. 10.1038/s41551-022-01000-210.1038/s41551-022-01000-2 ↗
47. 10.1016/j.drup.2015.10.00210.1016/j.drup.2015.10.002 ↗
48. 10.1016/j.biopha.2018.05.09110.1016/j.biopha.2018.05.091 ↗
49. 10.3389/fonc.2020.0119510.3389/fonc.2020.01195 ↗
50. Wood L. M. · Science · 2012 · 61 · 689
51. 10.1038/srep0474310.1038/srep04743 ↗
52. 10.1038/cddis.2013.15610.1038/cddis.2013.156 ↗
53. 10.1038/nrc338010.1038/nrc3380 ↗
54. 10.4110/in.2018.18.e2710.4110/in.2018.18.e27 ↗
55. 10.1126/sciadv.aaz446210.1126/sciadv.aaz4462 ↗
56. 10.1016/j.jconrel.2017.08.00910.1016/j.jconrel.2017.08.009 ↗
57. 10.1038/s41578-019-0110-710.1038/s41578-019-0110-7 ↗
58. 10.1038/nri325410.1038/nri3254 ↗
59. 10.1038/cr.2016.15710.1038/cr.2016.157 ↗
60. 10.1038/s41577-018-0088-110.1038/s41577-018-0088-1 ↗
61. Hilligan K. L. · AAAS Annu. Meet. Sci. Innov. Expo. · 2020 · 17 · 587
62. 10.1016/S0140-6736(18)33137-410.1016/S0140-6736(18)33137-4 ↗
63. 10.1016/j.critrevonc.2014.10.00610.1016/j.critrevonc.2014.10.006 ↗
64. 10.1001/jamaoncol.2019.627610.1001/jamaoncol.2019.6276 ↗
65. 10.1038/nrc325810.1038/nrc3258 ↗
66. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
67. 10.1038/s41578-021-00385-x10.1038/s41578-021-00385-x ↗
68. 10.1016/j.jconrel.2018.08.02410.1016/j.jconrel.2018.08.024 ↗